Cipla announced that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its API manufacturing facility in
Bommasandra, Bangalore from 20 January, 2020 to 24 January, 2020.
The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity. The Company is committed to address these observations and will submit its response to the USFDA within the stipulated time
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
